Population pharmacokinetic–pharmacodynamic modeling of PB2452, a monoclonal antibody fragment being developed as a ticagrelor reversal agent, in healthy volunteers

PB2452, a neutralizing monoclonal antibody fragment that binds the antiplatelet drug ticagrelor with high affinity, is being developed as a ticagrelor reversal agent. To identify a clinically useful intravenous (i.v.) reversal regimen, a semimechanistic exposure‐response model was developed during t...

Descripción completa

Detalles Bibliográficos
Autores principales: Kathman, Steven J., Wheeler, Jeffery J., Bhatt, Deepak L., Arnold, Susan E., Lee, John S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8752111/
https://www.ncbi.nlm.nih.gov/pubmed/34713987
http://dx.doi.org/10.1002/psp4.12734

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8752111/
https://www.ncbi.nlm.nih.gov/pubmed/34713987
http://dx.doi.org/10.1002/psp4.12734

Ejemplares similares